SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Staff Flag Reaction Risk With AstraZeneca PLC’s RSV Drug Motavizumab

May 28, 2010 | 
1 min read
WASHINGTON -(Dow Jones)- U.S. Food and Drug Administration staff said they are concerned about the risk for serious allergic reactions with a proposed AstraZeneca PLC (AZN) drug designed to prevent a respiratory infection in pre- term babies.
Regulatory
AstraZeneca Pharmaceuticals LP Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Trendy halftone collage. Concept of choice, make a decision left or right, ability to think in a difficult situation, question of choosing between 2 directions. Illustration for web banner, social media banner. Vector illustration
Tariffs
Trump Delays Pharma Tariffs Yet Again
October 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Difficult question concept. Big question mark or big problem to solve or finding solution, doubt or uncertainty, thinking to make decision, businessman holds up big question mark.
Drug pricing
Pfizer’s Drug Pricing Deal With Trump Raises Questions About Access
October 1, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
halftone magazine style banner, dislike, negative rating, hand thumbs down
Complete response letters
Fortress, Sentynl Fail To Secure FDA Nod in Rare Pediatric Disease
October 1, 2025
 · 
2 min read
 · 
Tristan Manalac
External view of the U.S. Capitol building
Government
US Government Shuts Down, FDA Closed for New Applications
October 1, 2025
 · 
4 min read
 · 
Annalee Armstrong